The new capabilities are available starting today, with some features in beta or public preview.

- Duchenne (SGT-003): 23 participants have been dosed in the INSPIRE DUCHENNE trial as of October 31, 2025; Solid expects to ...

Nirogacestat significantly improved progression-free survival and objective response rates in desmoid tumor patients compared ...

This valuable study examined the roles of the posterior parietal cortex in rats performing an auditory change-detection decision task. It provided solid evidence for two subpopulations with opposing ...

Topline phase 3 results show that the novel nanobody gefurulimab is safe and effective for AChR-antibody-positive myasthenia gravis, but long-term results will be key.

Objective Interstitial lung disease (ILD) represents the most common and severe organ manifestation observed in patients ...

Valentin George Cretu demonstrates how integrated planning enabled Mozambique LNG and created thousands of global jobs ...

PRESSADVANTAGE – StephenTwomey.com has released a new educational resource titled “The Ultimate Glossary of Hedge Fund, Private Equity & Alternative Investment Terms (2025 Guide)”, offering accredited ...

Over the past few days, medtech's biggest names gathered in San Francisco for the Transcatheter Cardiovascular Therapies (TCT ...

Guard Therapeutics (publ) today announced top-line results from the company's Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients un ...